Neurocrine Biosciences disclosed that NBI‑1070770, an oral compound licensed from Takeda for major depressive disorder, did not meet its primary endpoint in a Phase II trial. Company management said the drug was well tolerated but efficacy did not separate from placebo, and that they will further interrogate the dataset to determine next steps. This marks another midstage setback for Neurocrine programs sourced from the Takeda collaboration and intensifies focus on the company’s other late‑stage psychiatry assets. Neurocrine emphasized ongoing analysis and potential reallocation of resources to higher‑probability programs. Market reaction was muted relative to earlier expectations, and analysts suggested the company’s commercial performance from approved products will underpin near‑term financial stability while pipeline decisions are made.